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Abstract: The aim of the present study was to develop novel Mycobacterium bovis bacille
Calmette-Guérin (BCG)-loaded polymeric microparticles with optimized particle surface
characteristics and biocompatibility, so that whole live attenuated bacteria could be further used
for pre-exposure vaccination against Mycobacterium tuberculosis by the intranasal route. BCG was
encapsulated in chitosan and alginate microparticles through three different polyionic complexation
methods by high speed stirring. For comparison purposes, similar formulations were prepared with
high shear homogenization and sonication. Additional optimization studies were conducted with
polymers of different quality specifications in a wide range of pH values, and with three different
cryoprotectors. Particle morphology, size distribution, encapsulation efficiency, surface charge,
physicochemical properties and biocompatibility were assessed. Particles exhibited a micrometer size
and a spherical morphology. Chitosan addition to BCG shifted the bacilli surface charge from negative
zeta potential values to strongly positive ones. Chitosan of low molecular weight produced particle
suspensions of lower size distribution and higher stability, allowing efficient BCG encapsulation
and biocompatibility. Particle formulation consistency was improved when the availability of
functional groups from alginate and chitosan was close to stoichiometric proportion. Thus, the
herein described microparticulate system constitutes a promising strategy to deliver BCG vaccine by
the intranasal route.
Keywords: alginate; chitosan; BCG; microencapsulation; biocompatibility
1. Introduction
Enhanced immunization strategies must be urgently found for tuberculosis control [1,2]. The current
available vaccine used for pre-exposure vaccination against tuberculosis is Mycobacterium bovis
BCG. As with most vaccines nowadays, BCG is parenterally administrated by subcutaneous route.
This implies a relatively high production cost, the need for cold chain, and the need for trained
personnel for vaccine administration, while it also leads to lower patient compliance. Regarding the
resulting immune response, parenterally delivered vaccines usually produce poor mucosal responses,
which is critical to preventing tuberculosis, as Mycobacterium tuberculosis normally enters the host
through mucosal surfaces. The nasal route might therefore be an attractive alternative administration
route [3].
Regarding tuberculosis, it is essential for a new vaccine to better target the lungs while improving
interaction with antigen presenting cells (APCs) in the lung mucosa, such as alveolar macrophages [4].
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It is also well known that the eradication of Mycobacterium tuberculosis with pre-exposure vaccination
depends on adequate antigen presentation to amplify the elicited immune response, essentially cellular
Th1 types [5–8]. As such, whole live attenuated bacteria act as the ideal antigen producers and vectors,
as they are multigenic and normally mimic pathogens and surpass natural barriers.
In recent decades, several studies have elucidated the pros and cons of the nasal route for vaccine
administration. It is well known that, for soluble antigens, limited absorption occurs at the nasal
mucosa due to physiological barriers (i.e., mucosal epithelium, rapid mucociliary clearance, protease
degradation) [9]. Many strategies have been proposed in order to surpass these barriers and to increase
the immunogenicity of intranasal delivered antigens, namely, the use of permeation enhancers, mucosal
adjuvants and nano- and microparticulate delivery systems [10,11]. Some studies refer to a boost in
the immune response due to an adjuvant effect of particulate delivery systems, combined with the use
of potent immunopotentiators, either present in the formulation or co-delivered with antigens [12–18].
Taking into consideration the aforementioned, it has been hypothesized that BCG bacilli
modification through encapsulation in polymeric microparticulate delivery systems could be
an alternative to the classical BCG vaccine, suitable for mucosal immunization. Thus, the main goal of
this work was to encapsulate whole live BCG into polymers with biocompatible and mucoadhesive
properties using only mild conditions, so that BCG viability was maintained and the biocompatibility
of the developed microparticulate delivery system was assured. Microencapsulation of BCG in
chitosan-alginate microparticles will allow the following to take place in vivo, in sequence: bacilli
desorption from the particle surface; degradation and erosion of the polymer network; release of
bacteria. Moreover, with the entrapment of BCG in polymeric microparticles, it is expected to change
the BCG recognition pattern by the immune system and to modulate the mechanism of cellular uptake
by APCs cells. The selection of the microsize range was related to the intrinsic length of BCG bacilli rod
of approximately 2–4 micrometers, whereas the preference for electropositively charged microparticles
depends on their ability to better interact with negatively charged mucin [19–21].
The use of biodegradable polymeric particles has been proposed as a promising approach to elicit
adequate immune responses, while protecting antigens from degradation [18]. The preparation of
polymeric particles can be achieved through a wide range of preparation methods, each one yielding
particle formation within a determined size range. For instance, nanoprecipitation and supercritical
fluid technology usually yield nanoparticles, whereas spray-drying and solvent evaporation may
produce nano- or microparticles depending on the experimental conditions [22,23]. It is generally
stated that, for nasal delivery of antigens, nanoparticles are more favorable than particles in the
microsize range, as nanoparticles are better taken up by the M-cells present in the nasal associated
lymphoid tissue (NALT), and better transported through the epithelial cells (by paracellular and
transcellular transference), thus, leading to increased local and systemic immune responses [24,25].
Nevertheless, microparticles sized up to 40 micron have also been described as successful in eliciting
immune responses through nasal administration [11,26–29].
The most commonly described biodegradable polymers are poly(D,L-lactide-co-glycolide) (PLGA)
and poly(L-lactide) (PLA); however, particle formation with PLGA and PLA occurs only in the presence
of organic solvents. This is a major drawback, for several reasons. Not only the use of organic solvents
may lead to relevant toxicological effects, it can also prompt antigen denaturation or hamper cellular
vaccine viability, while formulation methods usually require multiple steps and are time consuming.
In view of the aim of producing a live vaccine, the longer it takes to carry out the formulation steps, the
greater the possibility of losing some of the vaccine or of compromising cell viability, thereby reducing
the encapsulation efficiency and potency of the vaccine.
In this context, chitosan (a deacetylated form of chitin extracted from crustaceans), and sodium
alginate (a natural product extracted from algae belonging to the Phaeophyceae, mainly species
of Laminaria) were chosen to prepare polymeric microparticles by ionic cross-linking methods as
described elsewhere [30–35]. Both chitosan and alginate have been extensively studied as biomaterials
and pharmaceutical excipients due to their biodegradability and low toxicity, and have been included
Mar. Drugs 2016, 14, 90 3 of 30
in the composition of several foods and dietary supplements [36,37]. With ionic gelation methods,
particles are formed in a single step by a simple mechanism, usually involving two different
polymers and one complexation agent, by adding one polymer solution to the other one with stirring.
Most commonly described complexation agents used with chitosan and alginate are calcium chloride
and tripolyphosphate (TPP) [35,38].
The widespread use of polyionic complexation methods presents many advantages, such as
their simplicity, versatility and flexibility, being applicable for virtually all polymers which can
be polymerized in the presence of a complexation agent, while being easily adjusted by changing
a number of experimental parameters. During optimization studies, the formulation conditions can
be changed to obtain desired features, namely, particle size, encapsulation efficiency, surface charge,
biocompatibility profile, and production yield. The type of used polymers (i.e., chemical nature,
molecular weight, viscosity, purity, pH, and other relevant specifications), the polymer to polymer
mass ratio, the type and concentration of complexation agent, the homogenization type (i.e., shear,
speed and duration) and the polymer to antigen ratio are some of the variables which significantly
influence the particles’ characteristics. Furthermore, the mild preparation conditions of these methods
allow the encapsulation of antigens without degradation caused by high temperatures, oxidation or
hydrolysis, as with other commonly used techniques.
As previously stated, both chitosan and alginate have been extensively used in the preparation
of polymeric nano- and micro-particles for immunization purposes. Chitosan and its derivatives are
described to increase the absorption of macromolecules through epithelial membranes, and to increase both
antigen residence time and uptake at the mucosal site, due to its intrinsic mucoadhesiveness [11,39–44].
Chitosan has been used to prepare nano- and microparticles intended for nasal and oral delivery of
vaccines with great results, as chitosan particles were able to elicit strong systemic and local immune
responses to different antigens [16,24,25,34,41,45–53].
Alginates are block copolymers polysaccharides, composed of long homopolymeric regions of
mannuronate (M) and guluronate (G), as the result of the conversion of mannuronic and guluronic
acid through neutralization during extraction from its natural source. The proportion, distribution
and length of these blocks determine the chemical and physical properties of the alginate molecules.
While G-blocks provide gel-forming capacity, MM and MG units provide flexibility to the uronic acid
chains, with flexibility increasing in the order GG < MM < MG.
Alginates constitute a very versatile material, having numerous pharmaceutical applications
due to their gelling, film-forming, thickening and stabilizing properties. It is said that the improved
stability of chitosan formulations can be assessed by developing chitosan blends with another polymer,
namely sodium alginate [36]. Two other valuable properties of alginates are that they are water-soluble,
allowing gel formation without heating or cooling, and also that the alginate matrix allows the
entrapment of molecules by capillary forces, which remain free to migrate by diffusion, depending
on the size. These features make alginates attractive gelling biopolymers for cell encapsulation
purposes. Gel formation and gel structure are determined by alginate type and calcium salt (Ca2+),
being influenced by pH value, solubility and temperature. For instance, at lower pH values, alginate
gel is shrunk and a reduction of the pore size of alginate matrix can be achieved, especially in the
case of low G content alginate. As such, these components and factors must be matched in order to
optimise the overall formulation of alginate microparticles by ionotropic gelation.
The formulation studies presented in this work aimed the optimization of the preparation
conditions of BCG-loaded polymeric particles taking into consideration the final yield of production,
encapsulation efficiency, particle size distribution and surface charge. Therefore, variables such
as the type of polymer or of polymer blends, polymers solution pH value, the polymer/polymer
and BCG/polymers ratio, as well as the type and time of homogenization procedures and order of
polymers and counter ions solutions’ incorporation were studied. The herein described effects of
experimental conditions on critical features of microparticle formulations provide a processing window
for manipulating and optimizing particles in the microsize range for intended applications.
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The expected advantages of the herein described systems for vaccine delivery include the capacity
of polymeric microparticulate systems to increase antigen residence time (due to the differentiated
release profile in the presence of alginate and chitosan) and to enhance antigen interaction with the
cell surfaces. Moreover, due to chitosan’s and alginate’s mucoadhesiveness, microparticles would be
able to promote mucopenetration, thus increasing antigen delivery.
2. Results and Discussion
2.1. Characterization of Polymeric Microparticles
The purpose of this study was to optimize the experimental parameters to prepare BCG-loaded
polymeric microparticles intended for intranasal immunization studies, presenting suitable size distribution
or surface charge, critical aspects for vaccine delivery. Therefore, the conditions for microparticle
preparation were optimized during preliminary formulation studies. Two polymers—chitosan and
sodium alginate—with different quality specifications (molecular weight, viscosity, G-content,
deacetylation degree, purity) were used to prepare plain polymeric microparticles, followed by
BCG microencapsulation. The prepared polymeric microparticles were characterized considering
particle size distribution, surface charge, morphology, and the final yield of production. FT-IR studies
were conducted in order to assess the interaction between chitosan and alginate ionic groups.
Particle size was the leading assessed property during formulation optimization studies, oriented
towards obtaining microparticles with a mean diameter of 5–10 µm, with a narrow and reproducible
size distribution. Another key aspect regarding the preparation of vaccine-loaded polymeric particles
is encapsulation efficiency, which should be as high as possible. Biocompatibility of the prepared
polymeric microparticles was determined in a cell viability MTT assay, using a human monocyte cell
line (THP-1) differentiated into macrophage-like cells, as a model for antigen presenting cells [54,55].
2.1.1. Size Distribution and Surface Charge
Previous studies showed that particle size distribution of plain polymeric microparticles prepared
by ionic gelation was greatly influenced by the polymers’ mass ratio and molecular weight [20,56,57].
Therefore, 14 formulations were initially developed with an alginate to chitosan mass ratio (ALG/CS)
ranging from 0.02:1 to 4.23:1 (w/w), according to described Methods I and II, using different
combinations of low viscosity (LV) alginate and low molecular weight (LMW) chitosan, medium
viscosity (MV) alginate and medium molecular weight (MMW) chitosan, and high viscosity (HV)
alginate and high molecular weight (HMW) chitosan. Microparticles were characterised for size
distribution (mean diameter and span) and surface charge (zeta potential).
The effect of polymer molecular weight with increasing alginate to chitosan mass ratio on particle
size distribution is presented in Table 1. Regarding the use of low molecular weight chitosan, particles
ranging from 18 to 34 µm were obtained with a narrow size distribution (span < 2.5) (Table 1).
Using chitosan of medium molecular weight yielded a general increase in particle mean diameter, with
formulation F13 (0.8:1 alginate to chitosan mass ratio, w/w) being the only exception. Using chitosan
of high molecular weight led to an intermediate particle mean diameter, except also for F13 (Table 1).
Herein presented formulations were obtained with a relatively narrow size distribution (span ď 5),
except for formulation F11 prepared with low molecular weight chitosan (span = 9.5). The obtained
span values suggest that particles are formed with better consistency when the availability of the
functional groups is close to stoichiometric proportion.
Broad particle size distributions can be attributed to the presence of larger single particles, which
in turn might prompt aggregate formation [58,59]. By visual inspection, we confirmed the presence of
aggregates mainly in formulations obtained with polymers of high MW (Figure 1). Best formulations,
defined as suitable to yield turbid solution without aggregation, were obtained with chitosan of
medium molecular weight when ALG/CS mass ratio ranged from 0.6:1 to 0.12:1, and with chitosan of
low molecular weight when ALG/CS mass ratio ranged from 0.4:1 to 1:1.
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Table 1. Particle size distribution (mean diameter and span) and surface charge (zeta potential) of
microparticles on the preparation day.
Formulation ALG:CS MassRatio (w/w)
Chitosan
MW
Particle Size,
d0.5 (µm) Span
Zeta Potential
(mV)
Production Yield
(%)
F0
Low 18.5 ˘ 0.7 1.4 ˘ 0.0 ´20.8 ˘ 7.9 n.d.
4.23:1 Medium 260.5 ˘ 41.3 4.3 ˘ 0.6 ´26.7 ˘ 4.9 n.d.
High 68.1 ˘ 10.6 5.2 ˘ 2.9 ´17.9 ˘ 6.8 n.d.
F11
Low 37.1 ˘ 0.7 9.5 ˘ 0.5 +34.0 ˘ 0.5 n.d.
0.4:1 Medium 144.4 ˘ 5.1 3.0 ˘ 0.1 +47.1 ˘ 1.7 n.d.
High 107.5 ˘ 10.1 4.1 ˘ 0.9 +30.4 ˘ 1.4 n.d.
F12
Low 39.3 ˘ 2.0 2.6 ˘ 0.1 +26.7 ˘ 1.1 n.d.
0.6:1 Medium 94.7 ˘ 3.2 3.7 ˘ 0.2 +30.9 ˘ 1.1 n.d.
High 65.9 ˘ 4.4 4.1 ˘ 0.7 +25.5 ˘ 0.5 n.d.
F13
Low 33.8 ˘ 0.9 2.6 ˘ 0.1 +22.7 ˘ 1.6 83.6 ˘ 0.0
0.8:1 Medium 23.9 ˘ 0.6 2.7 ˘ 0.3 +25.6 ˘ 1.8 n.d.
High 51.3 ˘ 1.8 3.3 ˘ 0.1 ´0.2 ˘ 0.8 n.d.
F14
Low 25.9 ˘ 0.7 1.7 ˘ 0.1 +16.2 ˘ 0.6 36.8 ˘ 0.0
1:1 Medium 139.0 ˘ 8.5 3.2 ˘ 0.1 ´10.9 ˘ 1.6 n.d.
High 80.6 ˘ 3.8 4.9 ˘ 0.2 ´25.7 ˘ 3.3 n.d.
F0, microparticles obtained by Method (I) via alginate ionotropic pre-gelation with CaCl2 followed by chitosan
addition; F11-F14, microparticles, obtained by Method (II) via chitosan pre-gelation with alginate, followed by
TPP (pH 9.0) addition. The pH of alginate and chitosan solutions was initially set to 4.9 and 4.6, respectively.
Microparticle size is characterized using the size distribution parameters d0.1, d0.5 and d0.9 (diameter for which
10%, 50% and 90% of the size distribution falls below, respectively) and span (width of particle size distribution,
according to the formula (d0.1´ d0.9)/d0.5). Results are expressed as mean and standard deviation (ně3). n.d.,
not determined.
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Figure 1. Microparticles domain formation using high, medium and low molecular weight chitosan.
The pH of alginate and chitosan solutions was initially set to 4.9 and 4.6, respectively. Three different
systems were identified: clear solution (), opalescent/colloidal suspension (), and aggregates (N).
The obtained results show a greater influence of chitosan molecular weight than alginate to
chitosan mass ratio on microparticles size distribution. Overall, the use of chitosan of low molecular
weight led to the formation of smaller particles for the majority of ALG/CS mass ratios, resulting in
fewer aggregates. This may stem from the ability of chitosan of low molecular weight to diffuse more
promptly in the alginate gel matrix to form smaller, more homogeneous particles, whereas, on the
contrary, polymers of high molecular weight or viscosity may bind to the surface of such matrices,
forming an outer membrane and leading to increment particle size [33,60].
The effect of polymer molecular weight with increasing alginate to chitosan mass ratio on particle
surface charge is presented in Figure 2. Alginate to chitosan mass ratios ranging from 0.4:1 to 0.8:1
led to the formation of microparticles with high positive zeta potential values (+22.7 ˘ 1.6 mV to
+47.1 ˘ 1.7 mV), thus, being positively charged, except for one formulation (F13 prepared with chitosan
of high molecular weight) (´0.2 ˘ 0.8 mV). Higher ALG/CS mass ratios (1:1 and 4.23:1) led to the
formation of negatively charged microparticles (´10.9 ˘ 1.6 mV to ´26.7 ˘ 4.9 mV) with increasing
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molecular weight (∆). Results are presented as mean ± SD (n ≥ 3). 
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liquid suspension. For chitosan‐alginate microparticles, surface charge greatly depends on chitosan 
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complexation agent, in alternative to TPP, it was possible to improve particle size distribution with 
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Figure 2. Effect of alginate to chitosan mass ratio on particle surface charge. The pH of alginate and
chitosan solutions was initially set to 4.9 and 4.6, respectively. Zeta potential of microparticles prepared
with chitosan of low molecular weight (˝), medium molecular weight (
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Zeta potential values provide qu ntitative measure of th charge on colloidal particles in liquid
suspension. For chitosan-alginate microparticles, surface charge greatly depends on chitosan total
protonated amino groups. Zeta potential profiles of ˘30 mV are described to prevent aggregation and
stabilize particles in suspension [61]. This was also confirmed by visual inspection of the obtained
colloidal suspensions, which remained stable without aggregation at room temperature for several
days (data not shown).
As for the formulation method, complexation with TPP performed best with 1:1 ALG/CS mass
and chitosan of low molecular weight (“F14_Lo ”), with microparticles presenting a mean diameter of
25.9˘ 0.7 µm, spanď1.7, and positive surface charge (+22.7˘ 1.6 mV). By using CaCl2 as complexation
agent, in alternativ to TPP, it was possible to improve particle size distribution with 4.23:1 ALG/CS
mass ratio and chitosan of low molecular weight (“F0_Low”), with microparticles presenting a reduced
mean diameter of 18.5 ˘ 0.7 µm (span ď1.4), and negative surface charge (´20.8 ˘ 7.9 mV).
These results indicate that the molecular weight of the chitosan used to prepare the microparticles
had a major impact in particle size distribution, whereas the alginate to chitosan mass ratio had an
important role in modulating particle surface charge. It was also possible to identify the conditions
which led to a greater heterogeneity in particle formation, evidenced as a broader particle size
distribution reve led in increase span values. Overall, it was possible to observe, for microparticles
prepared with a given ALG/CS m ss ra o, a higher standard deviatio of the spa when chi osan
of medium and high molecular weight were used (with f rmulation F11 being the exception), thus,
indicating that particle size distribution varied considerably and was not completely reproducible.
These results were important to put into evidence how to modulate the microparticles size distribution
and surface charge profile according to the selected formulation method.
Particle size is determinant in intranasal delivery and mucosal uptake of particles [29], and in the
intracellular traffic of the particles [62,63]. Carriers sizing few microns have shown higher potential
as intranasal delivery systems of antigens [64–66]. As size is increased, which can be partially due to
the increas in the sample mass by weight of the microp rticles, surface ar a decreases; this i turn
might contri ute to a slowdown in the antigen release rate as a depot effect. For the purpose of this
study, particle size should be at least 5 µm, in ord r to enable the entrapment of BCG bacilli, which
are short to moderate long rods, 0.3–0.6 ˆ 1–4 µm [67,68]. According to some authors, size must not
be greater than 10 µm when phagocytosis is required, with 200 nm to 5 µm being the ideal size [69].
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Nevertheless, much larger particles ranging from 1 to 40 µm have been successfully used for intranasal
immunization, eliciting good systemic and mucosal responses in mice [9].
Concomitantly with particle size distribution, zeta potential determination allows the estimation
of particle suspension stability against subsequent aggregation, as ˘30 mV can be an indicator
of the particulate systems’ stability [70,71]. Surface charge is a critical parameter that affects the
mucoadhesion of chitosan/alginate microparticles to the lung mucosa, which in turn will prolong
the residence time of the vaccine at the site of action. The net positive charge indicates the presence
of free surface amino groups in F11–F13 in addition to F14 obtained with chitosan of low molecular
weight, which will help in initial adhesion to nasal mucosa. Since mucoadhesive properties of chitosan
are mainly explained by the electrostatic interaction and by hydrogen bond of amine groups of this
cationic polymer with the negatively charged mucin [36], one can expect positively charged particles
to be preferable to negatively charged ones.
Taking into consideration the aforementioned results, it was possible to conclude that the
association of 4.23:1 ALG/CS mass ratio (formulation F0) and low molecular weight chitosan provided
the formulation’s optimal conditions to obtain polymeric microparticles with smaller mean diameter
(+18.5 ˘ 0.7 µm) and narrower particle size distribution (span = 1.4), also with negative surface charge
(´20.8 ˘ 7.9 mV). However, considering that our proposed microparticulate delivery system must be
suitable not only to encapsulate whole live BCG bacteria, but also to target the lung mucosa, positively
charged particles are expected to be preferable. Therefore, particle size distribution and particle surface
charge were considered together, and the 1:1 ALG/CS mass ratio formulation (F14) prepared with
chitosan of low molecular weight, with a microparticle size distribution of +25.9 ˘ 0.7 µm (span = 1.7)
and positive surface charge (+16.2 ˘ 0.6 mV), was chosen to for formulation optimization studies.
Effect of Homogenization Method
Preliminary formulation studies showed that particle size distribution of plain polymeric
microparticles prepared with the ionic gelation methods was greatly influenced by the type and
time of homogenization. Therefore, different homogenization methods were assessed in four different
formulations (F0, F12, F13 and F14), in order to obtain microparticles of desired and consistent size
distribution. The effect of high-speed homogenization (ultra-turrax, UT) and ultrasonication (US) used
for particle preparation with increasing ALG/CS mass ratios of the final formulation is presented
in Table 2.
The homogenization by ultrasonication led to the formation of microparticles within a narrower
and smaller size range, with mean diameters between 10.8 µm (“F13_Low”) and 14.4 µm (“F14_Low”),
and high production yields (>80%) (Table 2). When high-speed homogenization was used, the overall
mean diameter of the obtained microparticles greatly increased (Table 2). The use of chitosan of low
and high molecular weights resulted in more consistent and reproducible formulation methods, as the
size distribution of microparticles with different ALG/CS mass ratios and within the same chitosan
molecular weight presented a narrower size distribution, represented by a lower span (Table 2).
Taking into consideration the obtained results, and regarding particle size distribution, method
consistency and production yield, we selected formulations “F13_Medium MW chitosan” and
“F14_Low MW chitosan” for further optimization studies. In fact, although ultrasonication proved
to be effective in the preparation of plain chitosan-alginate microparticles, the ultimate goal was to
encapsulate whole live bacilli of BCG. Since both high shear and ultrasonication are said to compromise
cell viability, due to the induced cell integrity loss, two alternative homogenization methods were
investigated, namely, simple dispersion with a micropipette, or, alternatively, homogenization in
an ultrasound water-bath. Increasing homogenization times were evaluated.
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Table 2. Size distribution of polymeric microparticles prepared by high-speed homogenization and
ultrasonication, and yield of production.
Formulation_Chitosan MW
High-Speed Homogenization Ultrasonication
Particle Size,
d0.5 (µm) Span
Production
Yield (%)
Particle Size,
d0.5 (µm) Span
Production
Yield (%)
F0_Low 34.5 ˘ 1.8 6.7 ˘ 0.5 n.d. 67.8 ˘ 10.6 5.6 ˘ 0.9 n.d.
F0_Medium 47.8 ˘ 2.2 4.1 ˘ 0.4 n.d. 11.5 ˘ 3.2 8.8 ˘ 1.3 n.d.
F0_High 91.8 ˘ 1.6 3.4 ˘ 0.1 n.d. 69.5 ˘ 9.9 6.5 ˘ 0.8 n.d.
F12_Low 30.2 ˘ 0.3 3.0 ˘ 0.0 n.d. - - n.d.
F13_Low 20.4 ˘ 0.2 2.6 ˘ 0.0 n.d. 10.8 ˘ 0.6 6.7 ˘ 1.9 72.2 ˘ 0.0
F13_Medium 65.6 ˘ 1.7 3.5 ˘ 0.1 n.d. 11.8 ˘ 0.0 1.6 ˘ 0.0 97.3 ˘ 0.9
F13_High 52.9 ˘ 1.1 2.8 ˘ 0.0 n.d. 11.2 ˘ 0.4 4.7 ˘ 2.4 103.4 ˘ 2.6
F14_Low 25.2 ˘ 0.3 3.0 ˘ 0.0 53.8 ˘ 0.0 14.4 ˘ 0.3 1.2 ˘ 0.0 60.1 ˘ 10.7
F0, microparticles obtained by Method (I) with modifications, via alginate ionotropic pre-gelation with CaCl2
followed by chitosan addition; F12–F14, microparticles obtained by Method (II) with modifications, via chitosan
pre-gelation with alginate followed by precipitation with 2 mg/mL TPP (pH 9.0), with ALG/CS mass ratios
ranging from 0.6:1 to 1:1. The pH of alginate and chitosan solutions was initially set to 4.9 and 4.6, respectively.
MW, Molecular weight; n.d., not determined.
Particle mean diameter obtained for both formulations was within the 12.5–21.0 µm range
(Table 3). The best results were achieved with simple dispersion (“0 min”) for formulation “F14_Low”
(12.5 ˘ 0.2 µm;´14.9˘ 0.2 mV) and “20 min” in ultrasound water-bath for formulation “F13_Medium”
(12.6 ˘ 0.1 µm; +12.1 ˘ 0.9 mV). The use of the ultrasound allowed maintaining particle sizes
approximated to the desired particle size (10 µm). Particles were overall negatively charged, as
five formulations exhibited negative zeta potential values (´49.8 to ´14.1 mV), with formulation
“F13_Medium” being the one exception.
Table 3. Size distribution and zeta potential of microparticles prepared by homogenization in an
ultrasound water-bath, with increasing homogenization times.
Time
(min)
F13_Medium F14_Low
Particle Size,
d0.5 (µm) Span
Zeta Potential
(mV)
Particle Size,
d0.5 (µm) Span
Zeta Potential
(mV)
0 16.3 ˘ 0.1 2.0 ˘ 0.2 ´49.8 ˘ 0.7 12.5 ˘ 0.2 1.8 ˘ 0.4 ´14.9 ˘ 0.2
4 19.4 ˘ 0.6 2.4 ˘ 0.2 ´29.6 ˘ 1.2 15.7 ˘ 0.2 1.9 ˘ 0.2 ´19.5 ˘ 0.7
20 12.6 ˘ 0.1 2.0 ˘ 0.2 +12.1 ˘ 0.9 21.0 ˘ 0.3 1.6 ˘ 0.0 ´14.1 ˘ 0.5
F13_Medium, microparticles of 0.8:1 ALG/CS mass ratio prepared with medium molecular weight chitosan and
medium viscosity alginate Protanal™; F14_Low, microparticles of 1:1 ALG/CS mass ratio that were prepared
with low molecular weight chitosan and low viscosity alginate Protanal™. All microparticles obtained via
chitosan precipitation with TPP (pH 9.0) followed by addition of alginate (adapted from Method III). The pH of
alginate and chitosan solutions was initially set to 4.9 and 4.6, respectively. Medium and Low refers to chitosan
molecular weight and to alginate viscosity.
Particle size increased with increasing homogenization times, as such: from 12.5 to 21.0 µm to
“F14_Low” (0 to 20 min); from 16.3 to 19.4 µm to “F13_Medium” (0 to 4 min) (Table 3). Size distribution
of microparticles prepared with either 0.8:1 or 1:1 ALG/CS mass ratios, and different chitosan
molecular weight, presented with a narrow size distribution (low span) (Table 4), thus indicating
a good consistency of the used preparation method. Smaller particle sizes were obtained for F14
formulation at 0 and 4 min, compared to F13, probably due to a more favorable ALG/CS mass ratio,
as the stoichiometric proportion of alginate to chitosan of 1:1 might provide a better interaction and
nucleation between polymers, leading to smaller sized particles.
Mar. Drugs 2016, 14, 90 9 of 30
Table 4. Effect of pH on particle size distribution, particle surface charge, and yield of production of
microparticles prepared with alginate to chitosan mass ratio of 1:1 (F14_Low).
ALG pH CS pH F14 pH Particle Size,d0.5 (µm) Span
Zeta Potential
(mV)
Production
Yield * (%) Aggregates
3.0 3.0 3.3 44.2 ˘0.9 1.5 ˘ 0.0 +8.7 ˘0.1 6.4% Yes
4.0 3.0 3.6 31.3 ˘0.3 31.0 ˘ 16.3 +3.7 ˘0.0 12.5% Yes
5.0 3.0 3.9 16.1 ˘0.1 1.3 ˘ 0.0 ´3.5 ˘0.0 11.7%
6.4 3.0 4.0 15.2 ˘0.2 1.4 ˘ 0.1 ´4.6 ˘0.0 17.8%
7.0 3.0 4.0 18.0 ˘0.4 1.3 ˘ 0.0 ´2.3 ˘0.0 n.d.
3.0 4.0 4.1 43.8 ˘1.0 1.5 ˘ 0.0 +1.8 ˘0.0 16.9% Yes
4.0 4.0 4.3 19.0 ˘0.8 1.7 ˘ 0.0 ´4.9 ˘0.0 11.7% Yes
5.0 4.0 4.5 13.0 ˘0.3 2.0 ˘ 0.1 ´7.3 ˘0.1 13.6%
6.4 4.0 4.6 13.2 ˘0.7 1.7 ˘ 0.0 ´6.2 ˘0.1 11.9%
7.0 4.0 4.6 15.8 ˘0.4 1.8 ˘ 0.0 ´13.4 ˘0.1 18.3%
3.0 5.0 4.9 12.9 ˘0.5 6.3 ˘ 1.2 ´16.3 ˘0.0 10.4%
4.0 5.0 5.0 12.1 ˘0.4 3.1 ˘ 0.5 ´14.8 ˘0.0 11.4%
5.0 5.0 5.3 11.4 ˘0.3 3.6 ˘ 0.5 ´18.6 ˘0.1 6.7%
6.4 5.0 5.4 10.9 ˘0.4 2.7 ˘ 0.4 ´18.9 ˘0.1 11.4%
7.0 5.0 5.4 11.8 ˘0.3 2.8 ˘ 0.4 ´17.8 ˘0.1 10.6%
3.0 6.0 5.7 11.5 ˘0.2 5.2 ˘ 0.3 ´22.4 ˘0.1 8.3%
4.0 6.0 6.3 10.0 ˘0.7 7.1 ˘ 0.8 ´23.7 ˘0.2 14.2%
5.0 6.0 7.2 11.9 ˘0.3 4.9 ˘ 0.3 ´26.3 ˘0.1 14.6%
6.4 6.0 7.5 11.4 ˘0.2 3.3 ˘ 0.4 ´25.7 ˘0.1 n.d.
7.0 6.0 7.6 13.8 ˘0.3 2.3 ˘ 0.0 ´21.8 ˘0.2 n.d.
F14, microparticles obtained using formulation Method (III) with low molecular weight/92% deacetylation
degree chitosan (CS), and low viscosity / high-G sodium alginate (ALG) (Protanal™ LF 10/60). Results are
expressed as mean and standard deviation (n ě 3). *Production yield was determined using gravimetric
determination of particles mass following lyophilisation, and it is expressed as mass percentage (w/w), referred
to particles theoretical mass; n.d., not determined.
Effect of Alginate Type and Polymers Addition Order
The results obtained during formulation optimization studies led us towards the rejection of
Method (I) and the development of a different preparation method—Method (III). In order to evaluate
the effect of the polymers’ specifications on particle size distribution, three different sets of plain
microparticles were prepared using three different commercial brands of low viscosity sodium alginate
with distinct G-content, namely: low viscosity sodium alginate of high-G content (65%–75%) Protanal™
LF 10/60; ultra-low viscosity sodium alginate of high-G content (63%) Manugel™ LBA; low viscosity
sodium alginate of low-G content (40%) Keltone™ LVCR, all approved as pharmaceutical excipient.
Chitosan quality specification was kept constant; low molecular weight chitosan with a deacetylation
degree of 92% was used. Microparticles were prepared according to two different formulation
methods—Methods (II) and (III)—as described (Materials and Methods section) with modifications.
The two methods differ in the addition order of the polymers. By changing the polymers’ addition
order, it would be possible to modulate the final surface charge of microparticles.
Taking into consideration the aforementioned results obtained for particle size of “F14_Low”
prepared by simple dispersion (12.5 ˘ 0.2 µm), the same homogenization method to prepare these
microparticles was used, by simple dispersion with a micropipette for 1 min following additions. In
Method (II), chitosan and alginate were allowed to interact prior to TPP addition.
The effect of formulation Methods (II) and (III) with decreasing G-content of the sodium alginate
polymers used to prepare microparticles is presented in Figure 3. Regarding particle mean diameter
(Figure 3A), microparticles prepared with Method (II) presented a size distribution (d0.5) from
60.9 ˘ 5.5 µm (Protanal™) to 89.4 ˘ 6.7 µm (Manugel™). Changing the polymers’ addition order
by using Method (III) yielded a particle size distribution with a pronounced decrease in d0.5 values,
ranging from 14.7 ˘ 0.6 µm (Manugel™) to 24.0 ˘ 1.4 µm (Keltone™). No significant differences were
observed between alginates of different G-content within the same formulation method (p = 0.4634).
As for formulation Methods (II) and (III), it was possible to identify a bimodal particle size distribution
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depending on the used method. The observed differences were not, however, statistically significant
(p = 0.1000).
Regarding particle surface charge (Figure 3B), microparticles prepared with Method (II) presented
zeta potential values from +14.1 ˘ 0.6 mV (Protanal™) to ´16.3 ˘ 1.3 mV (Keltone™). Particle surface
charge decreased for all formulations when Method (III) was used, reaching negative zeta potential
values of ´29.6 ˘ 0.9 mV for Keltone™. Differences among the two evaluated methods were not
statistically significant (p = 0.4000). Nevertheless, the consistent decrease in zeta potential values
suggests that a reorganization of the chitosan-alginate matrix occurred when chitosan was allowed to
form a pre-gel with TPP, followed by alginate addition.
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weight and alginates of decreasing G‐content, according to Method (II) (□) and Method (III) (◌).The 
pH of alginate, chitosan and TPP solutions was initially set to 6.7, 4.1 and 9.0, respectively. Results 
are presented as mean ± SD (n = 3). 
These  results were  important  to  evidence how  the  addition order of  the polymers plays  an 
important  role  in  the  formation of  chitosan‐alginate microparticles. So  far,  it  seems  that ALG/CS 
mass ratio, homogenization method, and the addition order of the polymers have greater impact on 
particle size distribution and surface charge than the herein assessed G‐content of sodium alginate. 
Since Method (III) enabled the formation of microparticles with an inferior mean diameter, within a 
more  stable  colloidal  suspension,  it  was  chosen  as  the  formulation  method  for  the  following 
optimization studies. 
Effect of pH Value 
It  is well  established  that  an  ionic  complex between alginate and  chitosan  is  formed due  to 
interactions between the carboxyl groups of alginate with the amino groups of chitosan [35,56,70,71]. 
The  cationic nature of  chitosan  (pKa  ≈ 6.5)  is  conveyed by  the positively  charged –NH3+ groups, 
whereas the anionic nature of alginate (pKa ≈ 3.4–3.7) results from the presence of –COO− groups. 
The cationic nature of chitosan leads to the amino group protonation in acidic to neutral solution, 
with  charge  density  depending  on  pH  value  and  chitosan  deacetylation  degree.  These  features 
contribute to the solubility of chitosan in aqueous acidic solutions. Furthermore, it is key for chitosan 
bioadhesiveness,  since  chitosan  protonated  amino  groups  readily  bind  to  negatively  charged 
surfaces  such  as mucosal membranes,  and  for  the  enhancement  of  polar drugs  transport  across   
epithelial surfaces. 
In  order  to  assess  the  effect  of  pH  value  on  microparticle  formation,  several  sets  of 
microparticles from formulation “F14_Low” (ALG/CS mass ratio of 1:1, w/w) were prepared using 
1.0 mg/mL  solutions of  low molecular weight  92% deacetylated  chitosan,  and  low viscosity  and 
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Figure 3. (A) Particle size distribution of plain chitosan-alginate microparticles of 1:1 ALG/CS
mass ratio, prepared with chitosan of low molecular weight and alginates of decreasing G-content,
according to Method (II) (solid) and Method (III) (dashed); (B) Zeta potential of plain chitosan-alginate
microparticles of 1:1 ALG/CS mass ratio, prepared with chitosan of low molecular weight and alginates
of decreasing G-content, according to Method (II) (˝) and Method (III) (
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(n = 3).
These results wer imp rt nt to evidence ow the addition or er of the polymers plays an
important le in th formation of chitosan-alginate microparticles. So far, it seems that ALG/CS
mass ratio, homoge ization method, and the ddition order of the polymer have greater impact on
particle size di tribution and surface charge th n the herein assessed G-conte t f sodium alginate.
Since Method (III) en bled the f rmation of microparticles with n i ferior mean diameter, within
a ore stable colloidal suspension, it was chosen as the formulation method for the following
pti ization studies.
Effect of pH Value
It is well stablished that an ionic c mplex between alginate and chitosan is formed due to
interactions between the carboxyl groups of alginate with the amino groups of chitosan [35,56,70,71].
The cationic n ture of chitosan (pK « 6.5) is conveyed by the positively charged –NH3+ groups,
whereas the anionic nature of alginate (pKa « 3.4–3.7) results from the presence of –COO´ groups.
The cationic nature of chitosan leads to the amino group protonation in acidic to neutral solution,
with charge density depending on pH value and chitosan deacetylation degree. These features
contribute to the solubility of chitosan in aqueous acidic solutions. Furthermore, it is key for
chitosan bioadhesiveness, since chitosan protonated amino groups readily bind to negatively charged
surfaces such as mucosal membranes, and for the enhancement of polar drugs transport across
epithelial surfaces.
In order to assess the effect of pH value on microparticle formation, several sets of microparticles
from formulation “F14_Low” (ALG/CS mass ratio of 1:1, w/w) were prepared using 1.0 mg/mL
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solutions of low molecular weight 92% deacetylated chitosan, and low viscosity and high-G content
sodium alginate (Protanal™ LF 10/60), with pH value ranging from 3.0 to 7.0. The obtained suspensions
were characterized for particle size distribution, surface charge, and yield of production (Table 4).
The use of both alginate and chitosan solutions with a pH value below 5.0 resulted in increased
particle size (15 to 44 µm) and particle aggregation (Table 4). Aggregation also occurred when chitosan
solution pH was beyond 6.0 (data not shown), due to the loss of chitosan solubility, as chitosan has a
pKa value of « 6.5. Considering the desired particle size distribution (i.e., particle mean diameter of
approximately 10 µm, and narrow span), the optimal size distributions were obtained when chitosan
solution pH value was within 5.0–6.0, and alginate solution pH value within 4.0–6.4, leading to the
formation of 10–12 µm sized (d0.5) microparticles. Within this pH range, the carboxyl groups of
alginate are ionized, and the amine groups of chitosan are protonated, thus, favouring the optimum
interaction for the polyionic complex formation. All these formulations presented a negative particle
surface charge (Table 4).
The best system was obtained with formulation final pH value of 5.4, with particle mean diameter
of 10.9 ˘ 0.4 µm, a 2.7 span, and negative surface charge (´18.9 mV) (Table 4). These particles
were prepared with chitosan solution at pH = 5.0 and alginate solution pH = 6.4. Although it is
well known that the pH-dependent interaction between alginate and chitosan leads to the formation
of stronger complexes at a pH value around 4.5–5.0, it is also described that the amine groups of
chitosan (pKa « 6.5) have more affinity to alginate mannuronic acid (M) residues (pKM « 3.38) than to
guluronic acid (G) residues (pKG « 3.65) [36]. Since a high-G content («70%) alginate (Protanal LF™
10/60) was used, overall alginate pKa was closer to 3.65. This might explain why microparticles of
lower mean diameter (10.9 ˘ 0.4 µm) and narrower size distribution (span = 2.7) were obtained with
formulation final pH of 5.4. In fact, at this pH range, the high degree of protonation of chitosan amino
groups prompts a significant reaction with alginate carboxyl groups, leading to the formation of stable
particles. It would be expected that maximum ionic interaction occurs at a slightly lower pH value for
high-M content alginates (such as «60% M-content Keltone™ alginate).
The production yield was very low (<17%) for all formulations when determined by gravimetry
(Table 4). This is probably related to a low responsiveness of the gravimetric method for the determined
mass range, as mass variations occurred within the sub-milligram or micro-range. For that reason, the
described method in the Materials and Methods section (Section 3.4.2) based on the quantification of
chitosan concentration for the determination of the yield of production of microparticles was selected
for further studies. The results obtained were analysed by comparing the different pH conditions.
Regarding zeta potential results, microparticles prepared with the majority of pH combinations
were negatively charged (Table 4). This is probably due to the contribution of alginate carboxyl groups
to the negative net surface charge, therefore suggesting that the Method (III) provides the arrangement
of the polymeric matrix in such way that alginate somehow outers the chitosan particulate core.
It can be observed that particle mean diameter is significantly higher for microparticle suspensions
with final pH ď 4.3 (Table 4). At this pH value range, alginate approaches its pKa values, and
a significant part of alginate starts aggregating and precipitating, which might have contributed to the
increased particle mean diameter.
Effect of Cryoprotectants Addition
Table 5 summarizes the different batches of plain “F14_Low” microparticles prepared with
two concentrations (5% and 10%, w/v) of three different cryoprotectants. Microparticles were prepared
according to Method III with addition of cryoprotectant solution, consisting of sucrose, glucose, or
trehalose. Samples were prepared in triplicate. Particle size distribution and zeta potential of samples
were assessed for samples without cryoprotectant (batch A) and samples with cryoprotectant (batches
B to G), both prior to and after freeze-drying.
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Table 5. Characterization of plain chitosan-alginate microparticles (formulation “F14_Low”) batches
without (batch A) and with (batches B to H) cryoprotectants addition (sucrose, glucose, or trehalose),
on production day and following freeze-drying.
Batches Cryoprotectant% (w/v)
ALG:CS:Cryoprotectant
Mass Ratio (w/w)
Before Freeze-Drying After Freeze-Drying
Particle Size (µm) Zeta Potential
(mV)
Particle Size (µm)
d0.5 Span d0.5 Span
A - 1:1:0 13.3 ˘ 1.0 3.1 ˘ 2.3 ´19.5 ˘ 0.7 170.6 ˘ 50.8 2.6 ˘ 0.3
B Sucrose 5% 1:1:120 13.6 ˘ 0.2 1.8 ˘ 0.5 +14.9 ˘ 0.3 93.5 ˘ 15.6 2.3 ˘ 0.1
C Sucrose 10% 1:1:240 13.2 ˘ 1.1 1.4 ˘ 0.1 n.d. 65.5 ˘ 7.3 2.0 ˘ 0.2
D Glucose 5% 1:1:120 12.9 ˘ 0.0 1.8 ˘ 0.0 n.d. 54.1 ˘ 9.9 1.9 ˘ 0.3
E Glucose 10% 1:1:240 13.5 ˘ 2.0 2.0 ˘ 0.7 +11.6 ˘ 1.2 47.1 ˘ 8.3 2.4 ˘ 0.2
F Trehalose 5% 1:1:120 13.2 ˘ 0.4 1.8 ˘ 0.3 +13.3 ˘ 0.5 81.9 ˘ 15.5 2.0 ˘ 0.1
G Trehalose 10% 1:1:240 12.1 ˘ 0.6 1.4 ˘ 0.1 n.d. 63.7 ˘ 4.5 2.0 ˘ 0.3
The pH of alginate, chitosan and TPP solutions was initially set to 6.7, 4.1 and 9.0, respectively. Results are
expressed as mean and standard deviation (n ě 3); n.d., not determined.
The addition of cryoprotectants appears to have contributed to the modification of particle surface
charge (Table 5), as microparticles with no cryoprotectant (batch A) presented negative zeta potential
values (´19.5 ˘ 0.7 mV), whereas microparticles prepared with cryoprotectants (batches B, E and F, for
5% sucrose, 10% glucose and 5% trehalose, respectively) presented a positive surface charge, with zeta
potential values between +11.6 ˘ 1.2 mV and +14.9 ˘ 0.3 mV. This is probably due to the adsorption of
the molecules to the surface. It has been described that slightly acidic sucrose and glucose generate
a good isotonic medium (in terms of electrostatic stability) for negatively charged particles, but for
positively charged particles, as in the case of “F14_Low”, these additives reverse zeta potential [72].
Regarding particle mean diameter, it was within micrometer range for all prepared batches
(Table 5). With samples analyzed before freeze-drying (on production day), it was possible to
observe that there were no significant differences concerning particle size distribution (Table 5).
All batches presented similar size distributions, with average d0.5 values of 13.1 ˘ 0.5 µm, thus,
suggesting that addition of cryoprotectants did not influence particle size for batches prepared under
thesame conditions.
However, after freeze-drying, particle size distribution profile changed and all batches presented
up to 10-fold increased d0.5 values (Table 5), indicating a noteworthy increase of particle mean diameter,
probably due to the formation of larger particles or particle aggregates. This could also be seen in the
exacerbation of the d0.9 populations for all samples after freeze-drying (data not shown). Nevertheless,
the addition of cryoprotectants did prevent some aggregation following freeze-drying, as batch A
(particles with no cryoprotectant) presented the highest particle mean diameter, with approximately
two-fold higher d0.5 values assigned to batches where cryoprotectant had been added (batches B–G).
As for particle size distribution width, the obtained low span values (2.0 ˘ 0.5 µm, in average)
(Table 5) revealed a high similitude in particle size distribution, thus, suggesting that microparticle
preparation was reproducible. Microparticles prepared with 5% and 10% glucose (batches D and E,
respectively) performed best, with lower d0.5 values and low span values, thus, corresponding to
particles with a smaller, and narrow, particle size distribution.
It can be concluded that microparticle suspensions were affected by the nature and concentration
of cryoprotectants, with 10% glucose cryoprotectant (batch E) showing better properties after
freeze-drying, with smaller particle size, low span and average zeta potential positive value,
compared to microparticles with no cryoprotectant (batch A). Future studies must be conducted
with cryoprotectants in order to optimize particle size distribution and surface charge, so that the
physicochemical stability of microparticles after freeze-drying can be ensured.
2.1.2. Polymer–Polymer Interaction by FT-IR Analysis
Formation of microparticles of chitosan with alginate is a result of strong interactions by hydrogen
bonds between the functional groups of the polymers in which amino and amide groups present in
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chitosan take part. As a result, there are changes in the FT-IR spectra in the absorption bands of the
amino groups, carboxyl groups, and amide bonds [35]. Based on the identification of absorption bands
concerned with the vibrations of functional groups present in CS and ALG macromolecules [53], FT-IR
analysis was able to illustrate changes in the wave number and absorbance in the region of amino and
amide group vibrations with increasing pH of the microparticle suspension (Figure 4).
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Figure 4. FT-IR spectra of plain chitosan-alginate “F14_Low” microparticles (1:1 ALG/CS mass ratio)
with increasing pH of the microparticles suspension. Bands wave numbers (cm´1) are as follows: 1641
(amide bond), 1613 (symmetric COO´ stretching vibration), 1569 (strong protonated amino peak—from
partial N-deacetylation of chitin), and 1415 (asymmetric COO´ stretching vibration).
The FT-IR spectrum of microparticles produced with final pH of 4.0 and 5.7 reveals alginate
carboxyl peaks slightly shift from 1613 and 1415 cm´1 to 1609 and 1414 cm´1, respectively, after
complexation with chitos n. Both chitosan peaks were similarly shifte by a few cm´1 after
complexation with algina e, with the amide peak from 16 1 into singl t band at 1609 cm´1, and
the amino peak from 1559 to 1533 cm´1 or 1560 cm´1 at pH 4.0 and 5.7, respectively. The observed
changes in the bsorptio b nds of the amino groups, carboxyl groups, amide b nds can be
attributed to an ionic interaction between the carb nyl group of alginate and the amino group of
chit san. The peak absorbance of amino groups of chitosan at 1153 cm´1 was also present after
complexation, thus, suggesting an effective interaction between polymers at pH 4.0 and 5.7.
2.1.3. Surface Morphology
Microparticle morphology was characterized by microscopy. Both F13 and F14 microparticles
presented regular and smooth surfaces related to a generic spherical shape (Figure 5). Additionally, particle
size distribution observed in microscopic images was consistent with that obtained by laser diffraction,
revealing homogeneous populations of narrow particle size distribution (Figure 6).
Considering the results obtained during formulation optimization studies, F14_Low formulation,
produced with 1 mg/mL low MW chitosan (pH = 5.0) and 1 mg/mL Protanal™ sodium alginate
(pH = 6.4), the ‘simple dispersion’ method was chosen for further BCG encapsulation, so that a suitable
formulation of BCG-loaded microparticles can be developed and further assessed in immunization
studies. This formulation was chosen because it allowed the formation of microparticles of suitable
mean diameter and surface charge without aggregation, under mild conditions and only requiring
a few steps, critical for future sterile production during vaccine production.
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Figure 5. (A) Polarized light micrograph (100ˆ) of “F13_Medium” microparticles (0.8:1 ALG/CS)
prepared according to Method (III) with chitosan of medium molecular weight; (B) Contrast phase
micrograph (40ˆ) of “F14_Low” microparticles (1:1 ALG/CS) prepared according to Method (II) with
chitosan of low molecular weight.
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Figure 6. article size distribution of microparticles pro uced with alginate to chitosan ratio of
4.23:1 (F0), 0.8:1 (F13), and 1:1 (F14). F0 microparticles prepared according to Method (I) by alginate
ionotropic pre-gelation with CaCl2 follo ed by chitosan coating; F13-F14 microparticles prepared
according to Method (III) by chitosan pre-gelation with TPP followed by alginate coating. LMW, low
molecular weight chitosan; MMW, medium molecular weight chitosan; HMW, high molecular
weight chitosan.
2.2. Encapsulation Efficiency
The ability of chitosan/alginate microparticles to encapsulate Mycobacterium bovis BCG depends
to a great extent on bacteria surface charge. Therefore, zeta potential of Mycobacterium bovis BCG
Pasteur and rBCG-GFP strains was measured at low electrolyte concentration. In order to assess
the effect of experimental conditions on BCG bacilli surface charge, BCG strains were suspended in
different media, whereas BCG previously suspended in 0.9% NaCl was heat killed as it is described in
the Materials and Methods section (Table 6).
Both BCG Pasteur and rBCG-GFP bacilli presented predominantly negative zeta potential values
(Table 6). Overall, e surface charge of BCG Pasteur appears to b o ly slightly more electro-negative
than rBCG-GFP for all tested con itions. A different macr sc pic behavior of cell suspension was
also distinguishe —BCG P steur suspension formed a fluffy surface layer, which led to partial and
ephemeral aggregation; this phenomena was not observed for rBCG-GFP strain.
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Table 6. Surface charge of inactivated Mycobacterium bovis BCG (strains Pasteur and rBCG-GFP) bacilli
suspended in different media. Results are presented as mean ˘ SD (n = 3).
Inactivation Method Medium
Zeta Potential (mV)
BCG Pasteur rBCG-GFP
Temperature (80 ˝C, 151)
H2O ´39.3 ˘ 1.0 ´32.6 ˘ 1.0
Cell culture medium ´27.9 ˘ 2.7 ´21.2 ˘ 2.5
10 mM PBS ´20.4 ˘ 1.5 ´13.7 ˘ 1.4
0.9% NaCl ´29.9 ˘ 11.5 ´23.1 ˘ 11.0
0.025% low MW chitosan +83.9 ˘ 3.5 +90.6 ˘ 3.5
0.1% low MW chitosan +85.7 ˘ 12.1 +92.4 ˘ 11.9
The nature of the adsorbing species on the cell surface of the two strains might explain the
obtained variations. The negative surface charge for cells of all Mycobacterium BCG species arises from
the phosphate groups of phosphodiester linkages between the peptidoglycan and the arabinogalactan
of the basic cell wall structure which is common to all species of Mycobacteria [73]. Some hydrophobic
interaction involving lipid within the surface may also be involved, since the mycobacterial cell
envelope is a lipid-rich, complex structure that surrounds the bacillus and is thought to play a critical
role in the pathogenicity of Mycobacterium tuberculosis. A large number of mycobacterial lipoproteins
have been suggested to be important components for the synthesis of the mycobacterial cell envelope,
as well as for sensing processes, protection from stressful factors and host–pathogen interactions [74,75].
Zeta potential profiles showed no major differences between bacilli suspension in either 0.9%
NaCl, water, 10 mM PBS, or cell culture medium. However, when BCG bacilli from either strains
were suspended in low molecular weight chitosan, an inversion of zeta potential values occurred, in
a concentration dependent fashion, suggesting that the mechanism of association of the bacteria to chitosan
is, at least partially, mediated by ionic interaction between bacilli and chitosan. Other mechanisms, such
as hydrophobic interactions, might also be involved in bacteria microencapsulation.
Taking into consideration the abovementioned, it was hypothesised that the greatest
encapsulation/association efficiency for M. bovis BCG would be obtained by suspending BCG bacteria
in chitosan at a pH below its pKa (e.g., pH = 5), so that the polymer is predominantly positively
charged. Additionally, we chose to entrap monodisperse bacteria in chitosan microparticles by
means of controlled gelation of chitosan with TPP followed by alginate addition. In this way, a good
encapsulation efficiency was sought.
Preliminary formulation studies revealed that particle size distribution and surface charge were
influenced by the polymer to polymer mass ratio and the formulation method. Whether BCG
microencapsulation would have a great impact on microparticles features was uncertain, thus these
parameters were investigated. As such, BCG-loaded “F14_Low” microparticles (1:1 ALG/CS mass
ratio) were prepared as described in the Materials and Methods section (Section 3.3.1), by Method
(II) or Method (III), with modifications. The encapsulation efficiency was also determined. Table 7
summarizes the different batches of BCG-loaded “F14_Low” microparticles that were prepared and
the obtained results.
For microparticles prepared according to Method (II), BCG encapsulation led to decreased particle
size in comparison with plain microparticles. In opposition, for microparticles prepared according
to Method (III), BCG encapsulation led to increased particle size, referred to as plain microparticles
(Table 7). Within BCG-loaded microparticles, particle size increased in a concentration dependent
fashion, with increasing BCG loads of 8.3ˆ106, 1.7ˆ107, and 3.3ˆ107 CFU/mL for microparticles
prepared by Method (II), and with BCG loads of 8.3ˆ106 and 1.7ˆ107 CFU/mL for microparticles
prepared by Method (III) (Table 7).
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Table 7. Characterization of batches of BCG-loaded “F14_Low” microparticles prepared with increasing
concentrations of BCG.
Batches FormulationMethod
BCG Pasteur
Load (CFU/mL)
Particle Size,
d(0.5) (µm) Span
Zeta Potential
(mV) E.E. (%)
A II - 60.9 ˘ 5.5 3.0 ˘ 5.5 14.1 ˘ 0.6 –
B II 1.7ˆ106 35.3 ˘ 2.6 1.8 ˘ 0.1 10.5 ˘ 1.5 70.0 ˘ 1.6
C II 8.3ˆ106 39.3 ˘ 3.9 2.8 ˘ 1.8 12.9 ˘ 2.3 74.0 ˘ 3.9
D II 1.7ˆ107 41.0 ˘ 6.3 2.2 ˘ 0.1 11.8 ˘ 2.5 85.0 ˘ 4.8
E II 3.3ˆ107 36.8 ˘ 2.0 2.0 ˘ 0.2 13.0 ˘ 3.9 87.0 ˘ 3.4
F III - 18.2 ˘ 1.2 3.2 ˘ 0.7 ´3.2 ˘ 0.9 –
G III 1.7ˆ106 22.2 ˘ 1.0 6.5 ˘ 2.6 ´16.4 ˘ 2.1 –
H III 8.3ˆ106 28.3 ˘ 4.0 25.5 ˘ 12.3 ´12.7 ˘ 2.4 76.0 ˘ 1.4
I III 1.7ˆ107 22.5 ˘ 2.7 4.0 ˘ 2.8 ´13.7 ˘ 2.0 84.0 ˘ 3.4
J III 3.3ˆ107 21.4 ˘ 2.4 2.5 ˘ 0.4 ´12.2 ˘ 2.6 83.0 ˘ 10.7
Regarding particle surface charge, two different patterns were obtained, depending on the
formulation method (Table 7). Method (II) produced microparticles (both plain and BCG-loaded) that
were electropositively charged, with zeta potential values from +10.5 ˘ 1.5 mV to +14.1 ˘ 0.6 mV,
whereas Method (III) produced electronegatively charged microparticles (both plain and BCG-loaded),
with zeta potential values ranging from ´3.2 ˘ 0.9 mV to ´16.4 ˘ 2.1 mV. In comparison to plain
microparticles, BCG-loaded microparticles presented lower zeta potential values regardless of the used
formulation method (Table 7). These results indicate that negatively charged BCG bacilli is present,
thus, indicating that encapsulation occurred.
The encapsulation of BCG Pasteur into microparticles was efficient (70%–87% E.E.) and occred in
a concentration dependent fashion, regardless of the formulation method used (Table 7). The encapsulation
mechanism, however, was not determined. Due to the extremely high content of complex lipids
present in the BCG cell wall, it is extremely difficult and challenging to achieve efficient, uniform and
reproducible microencapsulation experiments. Therefore, we accept that BCG bacilli are sometimes
microencapsulated and other times just adsorbed due to partial and irregular adsorption onto the
microparticle surface.
2.3. BCG Cell Viability
Chitosan is described as having antimicrobial potential [48–50]. Whether BCG suspension in
chitosan would compromise BCG cell viability was uncertain. Therefore, BCG cell viability following
suspension in chitosan was investigated over time by a colony-forming units (CFUs) assay, as described
in the Materials and Methods (Section 3.3.1). Both strains BCG Pasteur and rBCG-GFP were assessed
in this cell viability study. Results are presented in Figure 7.
Results showed a significant reduction of BCG cell viability for both BCG strains, with small
differences (Figure 7A). For rBCG-GFP, viable cell density decreased 1 log on the 3rd week, and
approximately 3 log on the 6th week. Regarding BCG Pasteur, cell viability was further reduced,
with a viable cell density decrease of 1–2 log on the third week, and approximately 2.5–4 log on the
6th week. These effects were observed for both strains regardless of the suspension media (p > 0.05).
Overall, although the suspension of BCG in 0.025% chitosan induced a decrease in BCG cell viability,
the same effect was observed in the control groups of 0.9% NaCl-suspended BCG. Therefore, chitosan
may not be considered cytotoxic at the tested concentration. Figure 7B confirms that viable cell density
decreased approximately 1 log after 3 weeks for BCG-loaded chitosan-alginate microparticles and
for BCG suspended in 0.025% chitosan. Overall, the microencapsulation procedures preserved BCG
integrity and viability, as there were no statistically significant differences (P = 0.6314) in cell viability
losses between BCG-loaded microparticles and BCG suspended in 0.025% chitosan or in 0.9% NaCl.
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Figure 7. Cell viability of BCG  (A) After 3 weeks of  incubation, agar  (Middlebrook 7H10 medium 
supplemented with OADC) plates  inoculated with bacteria of both strains  (Pasteur and GFP)  that 
presented  a  number  of  colonies  of  statistical  relevance were  used  to  calculate  the  CFU/mL,  by 
multiplying  the  colony  forming units  by  the plating  factor  and  the dilution  factor. The CFU/mL 
provides an approximation of the cell density of the original culture. BCG suspension in 0.9% NaCl 
was used  as  control;  (B) BCG Pasteur viability  following BCG microencapsulation  in “F14_Low” 
chitosan‐alginate microparticles (no fill), BCG suspension in 0.025% low molecular weight chitosan 
weight (horizontal lines), or BCG suspension in 0.9% NaCl (angled lines). Results are expressed as 
mean ± S.D.; n = 3. 
2.4. In Vitro Cell Viability (MTT Assay) 
The in vitro biocompatibility of the microparticles was evaluated with the MTT assay using a 
PMA‐differentiated  THP‐1  cell  line  (Figure  8),  which  is  recommended  as  a model  for  antigen 
presenting cells [55]. 
Results  showed  no  significant  reduction  of  cellular  viability  after  24  h  incubation  with 
chitosan‐suspended BCG and BCG‐loaded microparticles, except  for  the highest concentrations of 
chitosan‐suspended BCG, namely, 25 μg/mL (p < 0.00001), 12.5 μg/mL (p = 0.0077) and 6.3 μg/mL (p < 
0.05), and a high  concentration of BCG‐loaded microparticles  (12.5  μg/mL). These  concentrations 
exceed concentrations  intended  for vaccination assays  (e.g., 25 μg/mL  is about  five  times higher). 
Overall, although some formulations induced a slight decrease in cell viability (15%–20%), none of 
the BCG‐loaded microparticles may be considered as cytotoxic since  the average values were not 
significantly different  from  the control group at  tested concentrations. The obtained results are  in 
conformity with other studies where chitosan did not interfere with cell viability [31]. 
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Figure  8.  Relative  cell  viability  of  THP‐1  cell  line  measured  by  the  MTT  reduction.  Columns: 
black—control  cells  with  culture  medium;  dark  grey—BCG‐GFP/0.9%  NaCl;  light 
grey—BCG‐GFP/0.025% LMW  chitosan; dotted white—BCG  Pasteur/F13_Medium microparticles; 
dotted  grey—BCG Pasteur/F13_High microparticles  (1  ×  108 CFUs/mL). Results  are  expressed  as 
mean ± SD (n = 3). Statistical differences between the control group and formulations are reported as: 
*** p < 0.001, ** p < 0.01, * p < 0.05. Cell viability (% of control) = [A] test/[A] control × 100. 
3. Materials and Methods 
3.1. Materials 
Sodium alginate polymers of high viscosity (14,000 mPa.s, 20 mg/mL), medium viscosity (3000 
mPa.s, 20 mg/mL; M/G ratio of 1.56), and low viscosity (187 mPa.s, 20 mg/mL) (27 mPa.s, 10 mg/mL; 
M/G  ratio  of  1.56)  were  purchased  from  Sigma‐Aldrich  (Dorset,  UK)  (structural  viscosity  as 
provided by suppliers). Other tested sodium alginates include: low G‐content (40%) Keltone LVCR 
(218 mPa.s,  20 mg/mL),  high G‐content  (63%) Manugel LBA  (773 mPa.s,  100 mg/mL),  and  high 
G‐content  (65%–75%) Protanal LF  10/60  (20–70 mPa.s,  10 mg/mL), which were  a  gift  from  FMC 
BioPolymer A.S. (Sandvika, Norway). Sodium tripolyphosphate (TPP) and calcium chloride (CaCl2) 
were  purchased  from  Sigma‐Aldrich  (Dorset,  UK).  Alginate  stock  solutions  were  prepared  in 
ultra‐purified water. 
Most  experiments  were  performed  using  solutions  containing  chitosan  of  low‐molecular 
weight  (<150 kDa) and deacetylation degree of 92%; chitosan of medium molecular weight  (<450 
kDa) and deacetylation degree of 85%; and chitosan of high molecular weight (≈600 kDa) or high 
structural viscosity (748 mPas, 1% in acetic acid 1%, 20 °C) and undefined deacetylation degree, all 
purchased  from  Sigma–Aldrich  (Dorset,  UK)  (specifications  as  provided  by  suppliers).  The 
molecular weights were  not  verified. Chitosan  stock  solutions were  prepared  in  1%  acetic  acid 
solution in ultra‐purified water. 
The BCG strains—M. bovis BCG Pasteur strain 1173 (ATCC 35734™) (American Type Culture 
Collection  (ATCC) Manassas,  VA, USA)and  a  recombinant M.  bovis  BCG  harboring  a  pMN437 
plasmid for expression of Green Fluorescent Protein (rBCG‐GFP) [76], were kindly supplied by Prof 
Elsa Anes  (FFUL). The bacterial cell culture  reagents were purchased  from Difco, Franklin Lakes, 
New Jersey, USA. Both M. bovis BCG Pasteur and rBCG‐GFP cultures were grown on Middlebrook’s 
7H9 broth Medium supplemented with 5% (v/v) OADC (oleic acid, albumin, dextrose and catalase 
supplement) at 37 °C/5% CO2. 
The  THP1  cells  (ATCC  TIB‐202™)  a  human monocyte  cell  line was  obtained  from  (ATCC, 
USA).  All  animal  cell  culture  reagents  were  purchased  from  Invitrogen  (Paisley,  UK).  Phorbol 
myristate acetate  (PMA), 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2H‐tetrazolium bromide  (MTT), 
dimethylsulfoxide (DMSO) were all from Sigma‐Aldrich (Dorset, UK). 
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Figure 8. Relative cell viability of THP-1 cell line measured by the MTT reduction.
Columns: black—control cells with culture medium; dark grey—BCG-GFP/0.9% NaCl; light
grey BCG-GFP/0.025% LMW chitosan; dotted white BCG Pasteur/F13_ edium microparticles;
dotted grey BCG Pasteur/F13_High icroparticles (1 ˆ 108 CFUs/mL). Results are expressed as
ean ˘ SD (n = 3). Statistical differences between the control group and formulations are reported as:
*** p < 0.001, ** p < 0.01, * p < 0.05. Cell viability (% of control) = [A] test/[A] control ˆ 100.
3. Materials and Methods
3.1. aterials
So i alginate polymers of high viscosity (14,000 mPa.s, 20 g/ L), medium viscosity
(3000 mPa.s, 20 mg/mL; M/G ratio of 1.56), and low viscosity (187 Pa.s, 20 mg/mL) (27 mPa.s,
10 mg/mL; M/G ratio of 1.56) were purchased from Sigma-Aldrich (Dorset, UK) (structural viscosity
as provided by suppliers). Other tested sodium alginates include: low G-content (40%) Keltone
LVCR (218 mPa.s, 20 mg/mL), high G-content (63%) Manugel LBA (773 mPa.s, 100 mg/mL), and
high G-content (65 –75%) Protanal LF 10/60 (20–70 mPa.s, 10 mg/mL), hich were a gift from
FMC BioPolymer A.S. (Sandvika, Norway). Sodium tripolyphosphate (TPP) and calcium chloride
(CaCl2) were purchased fro Sigma-Aldrich (Dorset, UK). Alginate stock solutions were prepared in
ultra-purifie ater.
ost experi ents were performed using solutions containing chitosan of low-molecular weight
(<150 kDa) and deacetylation degree of 92%; chitosan of mediu molecular weight (<450 kDa)
and deacetylation degree of 85%; and chitosan of high molecular weight («600 k a) or high
structural viscosity (748 Pas, 1 in acetic acid 1 , 20 ˝ ) and undefined deacetylation degree, all
purchased from Sigma–Aldrich (Dorset, UK) (specifications as provided by suppliers). The molecular
weights were not verified. Chitosan stock solutions were prepared in 1% acetic acid solution in
ultra-purified water.
The B strains . bovis B Pasteur strain 1173 ( T 35734 ) ( erican Type ulture
ollection (ATCC) Manassas, VA, USA)and a recombinant M. bovis BCG harboring a pMN437 plasmid
for expression of Green Fluorescent Protein (rBCG-GFP) [76], were kindly supplied by Prof Elsa Anes
(FFUL). The bacterial cell culture reagents were purchased from Difco, Franklin Lakes, New Jersey,
USA. Both M. bovis BCG Pasteur and rBCG-GFP cultures were grown on Middlebrook’s 7H9 broth
Medium supplemented with 5% (v/v) OADC (oleic acid, albumin, dextrose and catalase supplement)
at 37 ˝C/5% CO2.
The T P1 cells (ATC TIB-202™) a human monocyte cell line was obtained from (ATCC, USA).
All animal cell culture reagents were purchased from Invitrogen (Paisley, UK). Phorbol myristate acetate
(PMA), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), dimethylsulfoxide
(DMSO) were all from Sigma-Aldrich (Dorset, UK).
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3.2. Preparation of Polymeric Microparticles
Polymeric microparticles were initially prepared using modifications of previously described
ionic cross-linking methods [30–34], by high speed stirring at room temperature and without organic
solvents—Methods (I) and (II). Alginate and chitosan were dissolved in ultra-purified water.
In Method (I), polymeric microparticles were prepared via formation of an alginate ionotropic
pre-gel, by allowing sodium alginate solution to react with calcium chloride prior to chitosan addition.
(Figure 9). Briefly, a 7.5 mL aliquot of 18 mM calcium chloride solution was added drop wise into
a beaker containing 117.5 mL of a 0.6 mg/mL sodium alginate solution, and stirred for 60 min under
600 rpm, to provide an alginate pre-gel. Then, 25.0 mL of a 0.7 mg/mL chitosan solution was added
drop wise into the pre-gel and stirred over 90 min, giving a final alginate and chitosan concentration of
0.5 mg/mL and 0.1 mg/mL, respectively (alginate: chitosan mass ratio 4.23:1). A colloidal dispersion
formed upon polycationic chitosan addition.
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Figure  9.  Microparticles  formation  by  alginate  ionotropic  pre‐gelation  with  CaCl2  followed  by 
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In formulation Method (II), polymeric microparticles were prepared by allowing chitosan and 
sodium  alginate  to polymerize,  by means  of  ionic  interaction  between positively  charged  amine 
groups of chitosan and negatively charged carboxyl groups of alginate, prior to TPP addition (Figure 
10). Briefly, a 5.0 mL aliquot of 1.0 mg/mL chitosan were added drop wise into a beaker containing 
volume ranging from 0.1 to 5.0 mL of 1.0 mg/mL of sodium alginate solution, followed by dropwise 
addition of 1.0 mL of 1.0 mg/mL TPP under high‐speed stirring at 600  rpm  for 120–150 minutes. 
Alginate: chitosan ratios ranged from 0.02:1 to 1:1 (w:w). 
Figure 9. Microparticles formation by algin te ionotr pic pre-gelation with CaCl2 followed by chitosan
addition ( apted from [33]).
In formulation Method (II), polymeric microparticles were prepared by allowing chitosan and
sodium alginate to polymerize, by means of ionic interaction between positively charged amine groups
of chitosan and negatively charged carboxyl groups of alginate, prior to TPP addition (Figure 10).
Briefly, a 5.0 mL aliquot of 1.0 mg/mL chitosan were added drop wise into a beaker containing volume
ranging from 0.1 to 5.0 mL of 1.0 mg/mL of sodium alginate solution, followed by dropwise addition
of 1.0 mL of 1.0 mg/mL TPP under high-speed stirring at 600 rpm for 120–150 min. Alginate: chitosan
ratios ranged from 0.02:1 to 1:1 (w:w).
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Figure 10. Microparticles formation by chitosan gel matrix formation with sodium alginate followed 
by TPP addition (adapted from [32,34]). 
Preliminary  experiments  with  three  replicates  were  designed  in  order  to  investigate  the 
appropriate concentration range for chitosan, alginate and sodium tripolyphosphate, according to a 
previously described method  [32] with modifications  (Table  8). The purpose was  to  identify  the 
impact  of  the  key  components  of  the  polyelectrolyte  matrix,  such  as  different  pH  values  and 
polymers mass ratio, on parameters such as particle size and zeta potential. Therefore, high, medium 
and low molecular weight chitosan, and TPP, were used and their volume was kept constant (5.0 mL 
and 2.0 mL, respectively), while high, medium and  low viscosity alginate was used  in  increasing 
volumes. 
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(% w/v) 
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(w/w) 
F0  0.010  0.050  0.010 *  4.23:1 
F1  0.070  0.001  0.028 **  0.02:1 
F2  0.069  0.003  0.028 **  0.04:1 
F3  0.068  0.004  0.027 **  0.06:1 
F4  0.068  0.005  0.027 **  0.08:1 
F5  0.067  0.007  0.027 **  0.10:1 
F6  0.066  0.008  0.026 **  0.12:1 
F7  0.065  0.009  0.026 **  0.14:1 
F8  0.064  0.010  0.026 **  0.16:1 
F9  0.063  0.011  0.025 **  0.18:1 
F10  0.063  0.013  0.025 **  0.20:1 
F11  0.056  0.022  0.022 **  0.40:1 
F12  0.050  0.030  0.020 **  0.60:1 
F13  0.045  0.036  0.018 **  0.80:1 
F14  0.042  0.042  0.017 **  1.00:1 
Figure 10. Microparticles formation by chitosan gel at i i ith sodium alginate followed
by TPP addition (ad pted from [32,34]).
Preliminary experiments with three replicates were designed in order to investigate the
appropriate concentration range for chitosan, alginate and sodium tripolyphosphate, according to
a previously described method [32] with modifications (Table 8). The purpose was to identify the
impact of the key components of the polyelectrolyte matrix, such as different pH values and polymers
mass ratio, on parameters such as particle size and zeta potential. Therefore, high, medium and low
molecular weight chitosan, and TPP, were used and their volume was kept constant (5.0 mL and
2.0 mL, respectively), while high, medium and low viscosity alginate was used in increasing volumes.
Table 8. Values for the investigated variables ri f r l tion studies.
Formulation Chitosan (CS)(% w/v)
Alginate (ALG)
( /v)
CaCl2* or TPP **
(% w/v)
ALG:CS Mass Ratio
(w/w)
F0 0.010 0.050 0.010 * 4.23:1
F1 0.070 . 01 0. 28 ** 0.02:1
F2 0.069 . 03 0. 28 ** 0.04:1
F3 0.068 0.004 0.027 ** 0.06:1
F4 0.068 0.005 0.027 ** 0.08:1
F5 0.067 0.007 0.027 ** 0.10:1
F6 0.066 0.008 0.026 ** 0.12:1
F7 0.065 . 09 0. 26 ** 0.14:1
F8 0.064 0.010 0.026 ** 0.16:1
F9 0.063 0.011 0.025 ** 0.18:1
F10 0.063 0.013 0.025 ** 0.20:1
F11 0.056 0.022 0.022 ** 0.40:1
F12 0.050 . 30 0. 20 ** 0.60:1
F13 0.045 0.036 0.018 ** 0.80:1
F14 0.042 0.042 0.017 ** 1.00:1
F0—ALG/CS microparticles, obtained via alginate ionotropic pre-gelation with CaCl2 followed by chitosan
addition—Method (I); F1–F14—CS/ALG microparticles, obtained via chitosan precipitation with TPP followed
by gelation with alginate—Method (II). * CaCl2 ** TPP.
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High shear homogenization (ultra-turrax T10basic at 11,400 rpm, IKA-Labortechnik, Staufen,
Germany) and sonication (Branson Sonifier 250, equipped with a 3 mm microtip probe, BRANSON
Ultrasonics Corporation, Danbury, CT, USA) were assessed as potential alternatives to high speed
stirring to prepare microparticles. The techniques were evaluated considering physical stability of
microparticle suspensions (general aspect, formation of aggregates) and microparticles characteristics,
such as size distribution and surface charge. Microparticle preparation was in accordance with above
described formulation Method (I) and Method (II), with modifications. Briefly, in accordance with
previously described formulation Method (I), 0.75 mL of 18 mM calcium chloride were added to
11.75 mL of 0.6 mg/mL sodium alginate, and either homogenized for 3 min in ultra-turrax or sonicated
for 3 min at 20% output intensity, prior to 2.5 mL of 0.7 mg/mL chitosan addition, and subsequent
homogenization or sonication as described. As for Method (II), 5.0 mL of 1.0 mg/mL chitosan were
added to 0.1–5.0 mL of 1.0 mg/mL of sodium alginate, followed by addition of 1 mL of 2.0 mg/mL
TPP, and either homogenized for 3 min in ultra-turrax or sonicated for 3 min at 20% output intensity.
The results obtained during formulation optimization studies led us towards the rejection of
Method (I) and the development of a different preparation method—Method (III). In Method (III),
polymeric microparticles were prepared by inducing the pre-gelation of chitosan with TPP, followed
by alginate coating (Figure 11). Briefly, alginate and chitosan were dissolved in ultra-purified water.
Microparticles were formed by the dropwise addition of a 1.0 mL aliquot of 2.0 mg/mL TPP into
a beaker containing 5.0 mL of 1.0 mg/mL chitosan solution, followed by polyanionic cross linking
with volumes ranging from 0.1 mL to 5.0 mL of 1.0 mg/mL sodium alginate solution, also added drop
wise, under high-speed stirring at 600 rpm for 120–150 min.
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addition. 
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best  experimental  conditions  to  obtain microparticles  of  intended  size  distribution  and  surface 
charge.  In  these  studies, microparticles were prepared with  sodium  alginate  of different  quality 
Figure 1 . Microparticles formation by chitosan precipitation with TPP followed by alginate addition.
Additional characterization studies were conducted with Methods (II) and (III) to identify the
best experimental conditions to obtain microparticles of intended size distribution and surface charge.
In these studies, microparticles were prepared with sodium alginate of different quality specifications,
namely, viscosity and guluronic acid monomers content (G-content, %), and the influence of pH value
variations in microparticle size distribution and surface charge was determined. During pH value
studies, a wide range of chitosan- and sodium alginate-solution pH value was assessed (pH from 3.3
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to 7.6), while alginate (Protanal™ LF 10/60) concentration was kept constant at 0.1%. Modifications to the
formulation methods were introduced along the optimization process accordingly to the conclusions
yielded by the obtained results during preliminary studies. Regarding future lyophilisation of
microparticles, some preliminary studies using two concentrations (5% and 10% w/v) of three different
cryoprotectors (sucrose, glucose, and trehalose) were also conducted.
3.3. BCG Studies
3.3.1. BCG Single Cell Suspension
Bacterial cultures in exponential growth phase (after 7 days) were pelleted at 4000 rpm (1559ˆ g)
at 4 ˝C for 15 min, washed twice in sterile 10 mM PBS pH 7.4 and re-suspended in appropriate medium.
The suspension was kept on the bench for 5 min, to allow the decantation of the large clumps of
bacteria. Clumps of bacteria were removed by ultrasonic treatment of bacteria suspensions in an
ultrasonic water bath for 15 min. For bacteria remaining in clumps, the complete volume of the
suspension was collected and pressed through a 21 gauge needle against the syringe tube wall for
10 times, in order to get individualized bacilli.
Single cell suspension was confirmed by phase contrast microscopy or in a fluorescence
microscope (for rBCG-GFP). In the absence of clumps, the OD of the suspension at λ = 600 nm
was adjusted to 0.1 (we assumed that 0.1 OD600 corresponds to 1 ˆ 107 bacteria per mL [76]). This was
later confirmed by methylene blue staining and haematocytometer count (for BCG Pasteur) and
CFU counts after bacterial suspension plating, in order to more accurately determine the total viable
number of bacteria, as this can vary immensely as a function of the growth medium composition of
mycobacteria, and also due to a potential growth inhibition effect of chitosan [77–81].
3.3.2. Surface Charge Characterization
In order to modify the physicochemical properties of BCG, monodispersed bacteria were
suspended in different concentrations of chitosan and encapsulated or adsorbed into different
formulations of microparticles. Then, size distribution and surface charge were determined.
These studies were performed for both BCG Pasteur and rBCG-GFP strains. Inactivation studies
of both strains were also conducted to assess the effect of viability loss in BCG surface characteristics,
and to perform the further characterisation studies in safety. Mycobacteria were submitted to heat
inactivation, by submersion of 15 mL falcon containing bacterial suspensions in a water bath preheated
and maintained at 80 ˝C for 15 min [82]. The efficacy of inactivation methods was determined by
viability checks, as follows: 100 µL of the heat killed suspension was used to inoculate each of
two plates with solid agar Middlebrook 7H10 medium supplemented with 5% OADC and incubated
at 37 ˝C in 5% CO2 atmosphere for 3 weeks.
3.3.3. Microencapsulation of BCG
BCG-loaded microparticles were prepared by addition of 1.0 mL of whole live attenuated BCG
bacillus monodispersed in NaCl 0.9% (range, 1–2 ˆ 108 CFUs/mL) to 5.0 mL of 1.0 mg/mL chitosan
solution. Next, 1.0 mL of 2.0 mg/mL TPP was added drop wise to chitosan-suspended BCG, followed
by drop wise addition of 4.0 to 5.0 mL of 1.0 mg/mL sodium alginate solution to the mixture.
Final concentrations of prepared microparticles ranged from 6 to 8 log10 CFUs/mL and from 0.42 to
0.45 mg/mL of chitosan.
3.3.4. BCG Cell Viability
In order to assess BCG viability, a colony-forming units (CFUs) assay was used to count bacteria
of both strains (Pasteur and GFP) able to produce colonies in agar Middlebrook 7H10 medium
supplemented with OADC (widely used to cultivate and access the CFUs in the case of slow growers
such as M. tuberculosis and M. bovis BCG [77]). Briefly, aliquots of BCG suspended in 0.25 mg/mL
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chitosan of medium MW and BCG-loaded chitosan-alginate microparticles were seeded in appropriate
inoculation medium to determine the effects of processing conditions on cell viability. The samples
were maintained at 4 ˝C for approximately four months (15 weeks), and plates were inoculated with
samples for cell count at regular time points. After three weeks of incubation at 37 ˝C and 5% CO2,
colonies were counted to determine CFUs.
3.4. Characterization of Microparticles
3.4.1. Size Distribution, Surface Charge and Morphology
The microparticles were assessed according to size distribution and surface charge (zeta potential),
by laser diffraction and electrophoretic mobility, using a Mastersizer 2000 and a Malvern Zetasizer,
respectively (Malvern Instruments, Worcestershire, UK). For particle size analysis, each sample was
diluted with filtered purified water to the appropriate concentration to yield 10% obscurity limit.
Each analysis was carried out in triplicate at 25 ˝C. Results were expressed in terms of mean diameter
and span (Span = d (0.9) ´ d (0.1)/d (0.5)). Size distribution is characterized using the d0.5 parameter
(diameter for which 50% of the distribution falls below) and the span parameter (width of particle
size distribution). For the determination of the electrophoretic mobility, samples were diluted with
filtered purified water. The mean values were obtained from the analysis of three different batches,
each of them measured three times. Morphological examination of microparticles was performed by
microscopy. The ImageJ software, 1.44p version (National Institutes of Health, Bethesda, MA, USA)
was used to perform image analysis.
3.4.2. Production Yield
The production yield (YP) (Equation (1)) of the microparticles was determined using an indirect
method based on the quantification of the chitosan concentration initially used in the formulation,
and that found in the supernatant of the final microparticle suspension as previously published [29].
The method of quantification is based on a colorimetric reaction between amine groups of chitosan
and the dye Cibacron brilliant red 3B-A [30].
CS yield p%q “ rCSs total ´ rCSs supernantantrCSs total ˆ 100 (1)
3.4.3. Fourier Transform Infrared Spectroscopy (FT-IR) Analysis
Preliminary information on chemical nature of the chitosan-alginate microparticles was collected
using FT-IR analysis in an IRAffinity-1 (Shimadzu Corporation, Kyoto, Japan) spectrophotometer.
The FT-IR measurements were made directly in the dried microparticles, which were previously
lyophilised, and all powder raw materials namely chitosan and alginate, gently mixed with
approximately 300 mg of micronized KBr powder and compressed into discs at a force of 10 kN for
1 min using a manual tablet presser (Perkin Elmer, Norwalk, CA, USA). All spectra were recorded at
room temperature at the resolution of 4 cm´1 and 50-times scanning, between 4000 and 500 cm´1 [83].
3.4.4. Encapsulation Efficiency
Encapsulation efficiency (EE, %) was determined by cell count number using a haemocytometer
(Neubauer chamber Bürker). The encapsulation efficiency is expressed as the percentage of BCG
entrapped/adsorbed in microparticles reported to initial amount of cells in suspension (Equation (2)).
Encapsulation efficiency p%q “ Total cells´ Free cells
Total cells
ˆ 100 (2)
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3.5. In Vitro Cell Viability (MTT Assay)
Animal cell viability was assessed using general cell viability endpoint MTT as previously
described with some modification [30,73]. Briefly, THP-1 cells (grown in RPMI 1640 supplemented
with 10% FBS, penicillin and streptomycin,) were seeded onto 96 well cultures dishes at a density
of 5 ˆ 105 cells/mL and treated for 72 h with 20 nM PMA in order to differentiate into macrophage,
and medium exchanged and incubated for one more day. Cells were then incubated for 72 h at 37 ˝C
with different concentrations of CS and ALG solutions and BCG loaded and empty formulations.
Controls consisted of cells incubated with only culture medium. Each sample concentration was tested
in triplicate in a single experiment, which was repeated at least 3 times.
After the incubation time, culture medium was replaced with culture medium containing
0.5 mg/mL of MTT and incubated for 3 h at 37 ˝C. The medium was removed after 3 h and the
intracellular formazan crystals were solubilised and extracted with dimethylsulfoxide (DMSO).
After 15 min at room temperature, the absorbance of the extracted solution was measured at 570 nm
in a microplate reader (Infinite M200, Tecan, Männedorf, Switzerland). The percentage of cell viability
was determined for each concentration of tested sample according to Equation (3), where Abs test is
the absorbance value obtained for cells treated with samples, and Abs control is the absorbance value
obtained for cells incubated with culture medium.
Cell viability p% of Controlq “ Abs test
Abs control
ˆ 100 (3)
3.6. Statistical Analysis
Data were subjected to ANOVA for analysis of statistical significance, and a p value of <0.05 was
considered to be significant. Unless stated otherwise, results are expressed as mean values ˘ standard
deviation (SD). The analysis was carried out using GraphPad Prism v. 5.02 (GraphPad Software,
La Jolla, CA, USA).
4. Conclusions
During these formulation studies, it was possible to optimize the preparation method for
BCG-loaded chitosan-alginate microparticles with reproducible size distribution, encapsulation
efficiency and yield of preparation. Particle size and size distribution uniformity were considered to
be critical aspects throughout the formulation studies. These parameters are influenced by several
experimental conditions, such as the properties of the used polymers, antigen type (whole live bacteria
represent additional challenges regarding cell viability maintenance during formulation); type, speed
and duration of homogenization, polymer/polymer and polymer/complexation agent mass ratios,
and the relationship between the pH values of the different polymers.
In this study, biodegradable and biocompatible polymers (chitosan and sodium alginate), as well
as two strains of Mycobacterium bovis BCG (BCG Pasteur, clinically available vaccine; and rBCG-GFP),
were used. The number of variables that could be optimized was reduced throughout the formulation
development. Essentially, the optimization of the preparation method relied on the identification of
the best polymeric compositions and identification of the crucial steps in the ionic gelation methods
that were determinant for particle size distribution and surface charge.
It was possible to observe that, for chitosan-alginate microparticles, size distribution was mainly
influenced by the molecular weight of the used polymers and by the type of polymer blends. On the
contrary, particle surface charge was mainly influenced by polymer to polymer mass ratio due to the
possibility of particle aggregation. By simply suspending BCG in chitosan, it was possible to tune BCG
physicochemical properties, namely surface charge.
Additionally, the encapsulation of monodispersed whole live BCG bacilli into microparticles was
of paramount importance since it could directly influence BCG cell viability and particle size and
surface charge. It was possible to develop a reproducible method for microencapsulation of whole
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live bacteria using only mild conditions, through ionic cross-linking, with good production yield
and encapsulation efficiency, while maintaining cell viability and assuring the biocompatibility of the
developed microparticulate delivery system. The microencapsulation of BCG had no considerable
effect on particles key features (i.e., size distribution, surface charge, morphology). However, the
formulation method and, to a minor extent, the concentrations of BCG used, proved to be crucial in
achieving high encapsulation efficiency values.
Regarding particle surface charge, it was possible to demonstrate that the addition order of the
polymers was crucial to obtaining microparticles of either electronegative or electropositive surface
charge, as follows: Method (I) produced negatively charged particles, as chitosan droplets were
imprisoned in a previously formed, and stoichiometric predominant, alginate matrix); Method (II)
allowed the preparation of positively to negatively charged particles, depending on the polymer
mass ratio (Figure 2) or polymer specifications such as alginate G-content (Figure 3); and Method (III)
allowed the preparation of negatively charged particles, as alginate probably coated previously formed
chitosan particles. This was clearly shown with the empty particles (Tables 1, 3 and 4). As expected,
due to the negative surface charge of BCG bacilli, BCG encapsulation led to minor modifications of
the net charge at the particle surface (as depicted in Table 7), probably due to interference with the
polymer arrangement.
In conclusion, a whole, live attenuated, cell-based particulate delivery system was developed for
mucosal immunization purposes. Further characterization of these formulations in terms of in vitro
cellular interaction with macrophages and in vivo study following intranasal immunization in mice
is ongoing.
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Abbreviations
The following abbreviations are used in this manuscript:
ALG Alginate
APCs Antigen presenting cells
BCG Bacillus Calmette-Guérin
CFU Colony-forming unit
CS Chitosan
DMSO Dimethylsulfoxide
E.E. Encapsulation efficiency
FT-IR Fourier transform infrared spectroscopy
G Guluronate
GFP Green fluorescence protein
HMW High molecular weight
HV High viscosity
LMW Low molecular weight
LV Low viscosity
M Mannuronate
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MMW Medium molecular weight
MV Medium viscosity
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
NALT Nasal associated lymphoid tissue
ND Not determined
OADC Oleic acid, albumin, dextrose and catalase supplement
OD Optical density
PBS Phosphate-buffered saline solution
PLGA Poly(D,L-lactide-co-glycolide)
PLA Poly(L-lactide)
PMA Phorbol myristate acetate
rBCG Recombinant BCG
THP-1 human monocyte cell line
TPP Tripolyphosphate
US Ultrasonication
UT Ultraturrax
YP Yield of production
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